Search

Your search keyword '"Scanni, A."' showing total 503 results
Start Over Author "Scanni, A."
503 results on '"Scanni, A."'

202. Antithrombotic prophylaxis (AP) and catether-related infections in cancer patients (pts) carrying central venous devices (CVD): An observational study

Author

Antonio Ardizzoia, Camillo Porta, A. Scanni, Daniele Fagnani, Alessandro Bertolini, V. Filipazzi, M. Duro, Monica Giordano, R. Franchi, and Claudio Cimminiello

Subjects
Cancer Research, Central line, medicine.medical_specialty, business.industry, Cancer, Heparin, medicine.disease, Oncology, Internal medicine, Antithrombotic, Medicine, Observational study, business, medicine.drug
Abstract

18550 Background: Recent data underline the possibility to reduce catheter-related infections in cancer pts having placed a central line by using low-dose heparin. Here we report the results of an observational prospective study aimed at recording management and outcome, including infective complications, of pts affected by solid tumors undergoing a CVD placement. Methods: The study was named “Registro CVD-POLO NORD” and involved 18 centers of oncology in Lombardia (Italy). Starting from January 2003 and with an accrual period of 30 months, 1418 pts entered the study and their data were recorded. Both bloodstream infections and local infections of the subcutaneous pocket were considered as catheter-related infections. Results: On September 2005, 1253 pts had a follow-up of at least 4 months, the median follow-up period being 6 months. Of them, 424 subjects (34%) received a continuous AP consisting mainly of very low-dose warfarin. CVD-related infections occurred in 46 pts (3.6%, 95 CI 2.6%–4.7%). In the table the frequency of infective complications is reported according to type of cancer, stage of disease, treatment with chemotherapy (CT) and administration of AP. The use of central venous catheter (CVC) and peripherally inserted central catheter (PICC) as well as CT were significantly more associated with infections. On the contrary, low-dose warfarin appeared to be protective. No difference was found as regard to the primary tumor site. There were no major bleeding complications among subjects receiving AP. Conclusions: Confirmatory of previous reports, our data underscore the increased risk of infections related to the use of certain devices and CT administration. The role of fibrin deposition in favouring bacterial colonization of CVD seems to be confirmed by the protective effect of low-dose warfarin which represents a feasible way to obtain a long-term reduction of catheter-related infections. [Table: see text] No significant financial relationships to disclose.

Published
2006

203. Colorectal cancer screening: What do we know about it?

Author

L. Bertolusso, F. Cardin, P. Fracasso, Edoardo Benedetto, Enzo Ubaldi, S. Scanni, R. De Bastiani, M. Crespi, Luigi Napoli, A.P. Pati, Cesare Tosetti, D. Lisi, and Alberto Bozzani

Subjects
Oncology, medicine.medical_specialty, Hepatology, Colorectal cancer screening, business.industry, Internal medicine, Gastroenterology, medicine, business
Published
2006

205. Recurrent alveolar abscesses by bisphosphonates

Author

N. La Verde, R. Ratti, C. Mantica, S. Cobelli, A. Scanni, Gabriella Farina, R. Rovej, Mariastella Dimaiuta, Karen Borgonovo, and Donata Pedretti

Subjects
Cancer Research, medicine.medical_specialty, Oncology, business.industry, Internal medicine, medicine, Cancer, Disease, Pathological fractures, medicine.disease, business, Gastroenterology
Abstract

3211 Background: Cancer patients (pts) with bone metastases could have pain, pathological fractures, hypercalcemia. Bisphosphonates (B) are used in the management of disease, inhibiting osteoclasti...

Published
2005

206. Registro central venous devices (CVD) - Polonord

Author

Monica Giordano, Alessandro Bertolini, R. Franchi, Camillo Porta, Claudio Cimminiello, G. Aondio, Antonio Ardizzoia, A. Scanni, and Daniele Fagnani

Subjects
Cancer Research, medicine.medical_specialty, Oncology, business.industry, Emergency medicine, medicine, Observational study, cardiovascular diseases, Prospective cohort study, business
Abstract

8153 Background: The use of CVD (advantages and complications) has been studied with an observational prospective study, called “Registro CVD - PoloNord”, collecting all patients (pts) having place...

Published
2005

207. Prevention of chemo-induced cardiotoxicity by dexrazoxane (D)

Author

Gabriella Farina, A. Scanni, K. Borgonovo, R. Ratti, and M. Tomirotti

Subjects
inorganic chemicals, Cancer Research, medicine.medical_specialty, Cardiotoxicity, business.industry, fungi, food and beverages, medicine.disease, Oncology, Internal medicine, Heart failure, cardiovascular system, Cardiology, Medicine, Dexrazoxane, business, medicine.drug
Abstract

8281 Background: Anthracyclines (A) produce oxidative distress and cardiac heart failure (CHF) dose-related; D can reduce cardiotoxicity inhibiting onset of stable complex with Fe3+; we can limit t...

Published
2005

208. Epirubicine-vinorelbine (EV) intravenous combination followed by oral vinorelbine (VNR) as first-line treatment in advanced breast cancer (ABC) patients: A POLONORD Group study

Author

L. Isa, Daniele Fagnani, Antonio Ardizzoia, Luciano Frontini, Monica Giordano, Alessandro Bertolini, G. Scognamiglio, A. Scanni, T. Pressiani, and I. Colombo

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Group study, business.industry, Advanced breast, Cancer, Vinorelbine, medicine.disease, Surgery, carbohydrates (lipids), First line treatment, Internal medicine, polycyclic compounds, medicine, skin and connective tissue diseases, business, medicine.drug, Epirubicin
Abstract

770 Background: Epirubicin and Vinorelbine alone or in combination are considered active in ABC.The optimal duration of a chemotherapic treatment in ABC patients is not know. Otherwise Epirubicin h...

Published
2005

209. Oxaliplatin in Hepatic Arterial Infusion (Hai) and Systemic Chemotherapy with Leucovorin plus 5-fluorouracil in Metastatic Colorectal Cancer Preliminary Data of a Multicenter Study

Author

Perrone, S, primary, Pallavicini, E Bobbio, additional, Tacconi, F, additional, Inzoli, A, additional, Malingher, A, additional, Bianchessi, C, additional, Sbalzarini, G, additional, Signaroldi, A, additional, Zanaletti, F, additional, Rovej, R, additional, and Scanni, A, additional

Published
2002
Full Text
View/download PDF

212. Failure to Diagnose Colorectal Carcinoma at Colonoscopy

Author

P. Fracasso, L. Di Iorio, S. Scanni, and Omero Alessandro Paoluzi

Subjects
medicine.medical_specialty, Letter to the editor, medicine.diagnostic_test, business.industry, Colorectal cancer, General surgery, Gastroenterology, Medicine, Colonoscopy, business, medicine.disease
Published
2004

213. Preoperative chemo/radiotherapy with oxaliplatin and 5FU-AF in rectal cancer

Author

A. Fasolo, M. Botturi, Francesco Onida, Barbara Galassi, D. Asnaghi, P. Sburlati, A. Scanni, R. Rovej, M. Tomirotti, and K. Borgonovo

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Chemo-radiotherapy, business.industry, Colorectal cancer, medicine.medical_treatment, medicine.disease, Oxaliplatin, law.invention, Radiation therapy, Randomized controlled trial, law, Internal medicine, medicine, Overall survival, business, medicine.drug
Abstract

3744 Background: Randomized trials demonstrated that pre-operative radiotherapy reduces the risk of local relapse and increases of more than 10% the overall survival at 5 years. European trials are...

Published
2004

217. HER2 status in advanced breast cancer: which option for aromatase inhibitors?

Author

O. Fusco, A. Bertolini, G. Andreola, A. Scanni, A. Fasolo, S. Brugnatelli, A. Ardizzoia, G. Scognamiglio, Monica Giordano, and V. Filippazzi

Subjects
Oncology, medicine.medical_specialty, biology, business.industry, Advanced breast, Cancer, General Medicine, medicine.disease, Internal medicine, medicine, biology.protein, Surgery, Aromatase, business
Published
2003

222. Oxaliplatin in Hepatic Arterial Infusion (Hai) and Systemic Chemotherapy with Leucovorin plus 5-fluorouracil in Metastatic Colorectal Cancer Preliminary Data of a Multicenter Study

Author

A Signaroldi, F Tacconi, A Malingher, S Perrone, A. Scanni, Clara Bianchessi, E. Bobbio Pallavicini, G Sbalzarini, R Rovej, F Zanaletti, and Alessandro Inzoli

Subjects
Cancer Research, medicine.medical_specialty, Colorectal cancer, Systemic chemotherapy, business.industry, General Medicine, medicine.disease, Gastroenterology, Oxaliplatin, Hepatic arterial infusion, Oncology, Multicenter study, Fluorouracil, Internal medicine, medicine, business, medicine.drug
Published
2002

236. Prospective randomised trial comparing fluorouracil versus doxifluridine for the treatment of advanced colorectal cancer

Author

Bajetta, Emilio, primary, Colleoni, Marco, additional, Rosso, Riccardo, additional, Sobrero, Alberto, additional, Amadori, Dino, additional, Comella, Giuseppe, additional, Marangolo, Maurizio, additional, Scanni, Alberto, additional, Lorusso, Vito, additional, Calabresi, Federico, additional, Bonsignori, Maurizio, additional, Crivellari, Diana, additional, Pasquini, Enzo, additional, Bruzzi, Paolo, additional, Repetto, Marina, additional, and Criscuolo, Domenico, additional

Published
1993
Full Text
View/download PDF

239. Treatment of Carcinoid Syndrome with Recombinant Interferon Alpha-2a

Author

Di Bartolomeo, Maria, primary, Bajetta, Emilio, additional, Zilembo, Nicoletta, additional, de Braud, Filippo, additional, Di Leo, Angelo, additional, Verusio, Claudio, additional, D'aprile, Modesto, additional, Scanni, Alberto, additional, Iirillo, Antonio, additional, Barduagni, Aldo, additional, and Epifani, Cosimo, additional

Published
1993
Full Text
View/download PDF

241. Consensus Development Conference: Assessment of the Quality of Life in Cancer Clinical Trials

Author

Tamburini, Marcello, primary, Tomamichel, Michele, additional, Amadori, Dino, additional, Annunziata, Maria Antonietta, additional, Apolone, Giovanni, additional, Belli, Gianfranco, additional, Bonsignori, Maurizio, additional, Borreani, Claudia, additional, Buda, Patrizia, additional, Capovilla, Eleonora, additional, Caraceni, Augusto, additional, Cianfriglia, Francesco, additional, Corli, Oscar, additional, Costantini, Massimo, additional, De Carli, Gianfranco, additional, Filiberti, Antonio, additional, Fiorentino, Mario, additional, Frontini, Luciano, additional, Gamba, Alessio, additional, Gangeri, Laura, additional, Goldhrisch, Aron, additional, Labianca, Roberto, additional, Martini, Cinzia, additional, Mencaglia, Emanuela, additional, Morasso, Gabriella, additional, Nicosia, Francesco, additional, Paci, Eugenio, additional, Peruselli, Carlo, additional, Rosso, Stefano, additional, Sant, Milena, additional, Scancarello, Rosanna, additional, Scanni, Alberto, additional, Talamini, Renato, additional, Toscani, Franco, additional, Torri, Valter, additional, Trizzino, Giorgio, additional, Tumolo, Rino, additional, Valagussa, Pinuccia, additional, and Wuhrer, Cristina, additional

Published
1992
Full Text
View/download PDF

242. LE TRASFORMAZIONI DELL'ORGANIZZAZIONE D'IMPRESA E LA PROFESSIONALITÀ DEL LAVORATORE.

Author

Scanni, Ilaria

Subjects
PROFESSIONALISM, ORGANIZATIONAL change, ORGANIZATIONAL structure, ORGANIZATIONAL behavior, ORGANIZATIONAL learning, TECHNOLOGICAL unemployment, TECHNOLOGICAL innovations, INDUSTRIAL research
Abstract

Copyright of Sociologia del Diritto is the property of FrancoAngeli srl and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2011

243. Hodgkin's Disease in 50 Intravenous Drug Users with HIV-Infection

Author

Monfardini, S., primary, Tirelli, U., additional, Vaccher, E., additional, Errante, D., additional, Rezza, G., additional, Talamint, R., additional, Albericci, F., additional, Barbui, T., additional, Bernasconi, C., additional, Cajozzo, A., additional, Cargnel, A., additional, Clerici, M., additional, Lalla, De, additional, Dessalvi, P., additional, Fiaccadori, F., additional, Garavelli, P. L., additional, Giudici, M., additional, Gherlinzoni, F., additional, Deliliers, G. Lambertenghi, additional, Lazzarin, A., additional, Luzi, G., additional, Luzzati, R., additional, Malfitano, A., additional, Mandelli, F., additional, Marigo, S., additional, Montesarchio, V., additional, Moroni, N., additional, Puppo, F., additional, Raise, E., additional, Rizzardini, G., additional, Rizzi, M., additional, Rossi, E., additional, Saliva, G., additional, Scanni, A., additional, Sinicco, A., additional, Vaglia, A., additional, Foà, R., additional, and Gavosto, F., additional

Published
1991
Full Text
View/download PDF

244. 59 Tamoxifen (TAM) in breast cancer (BC): Toxicity of long term adjuvant treatment

Author

S. Cobelli, M. Tomirotti, Silvia Perrone, N. La Verde, A. Scanni, C. Mantica, Gabriella Farina, and M. Dambrosio

Subjects
Gynecology, Cancer Research, medicine.medical_specialty, Hysterectomy, business.industry, Endometrial cancer, medicine.medical_treatment, Cancer, macromolecular substances, medicine.disease, Gastroenterology, Endometrial hyperplasia, carbohydrates (lipids), stomatognathic diseases, Breast cancer, Oncology, Internal medicine, otorhinolaryngologic diseases, medicine, bacteria, Gallbladder cancer, Radical surgery, business, Stomach cancer
Abstract

To evaluate collateral effects of a TAM prolonged treatment, we analyzed, in a retrospective study, 243 pts, whose mean age was 59.2 years (27-85), all BC treated with radical surgery and adjuvant TAM for more than 2 years, 61/243 in premenopausal (25.1%) and 182/243 in postmenopausal age (74.9%). Twenty-nine out of 243 pts (11.9%) had a precedent hysterectomy for other benign gynaecological diseases. Fortythree pts (17.7%) received TAM 20 mg/die and 200 (82.3%) 30 mg/die; median treatment duration was 50.5 months (24-120 m) (front 2 to 3 years: 58 pts, from 3 to 4 years: 39 pts, from 4 to 5 years: 97 pts, > 5 years: 49 pts, in which TAM was readministrated as first line too). The median follow-up was 70.3 m (2-15 years). For intolerance, 22 (9.1%) pts reduced TAM from 30 to 20 mg/die while 12 (4.9%) pts stopped for the same problem. We reported these side effects: thrombophlebitis in 13 pts (5.3%), epigastralgia of mild entity in 18 pts (7.4%), leucopaenia grade I WHO in 5 pts (2.1%), thrombocytopenia grade II in 2 pts (0.8%), mild hyperglycemia in 15 pts (6.2%), mild nausea in 8 pts (3.3%), leukorrea in 5 pts (2.1%), flashing in 12 pts (4.9%), spotting from endometrial hyperplasia in 22/214 pts (10.3%). Only 3 pts had a contralateral BC (1.2%). We reported 4 gynaecological cancers (1.9%): 2 endometrial adenocarcinomas after 22 and 60 months of TAM treatment, 1 ovarian granulosa-cells tumor after 30 months and 1 ovarian tumor-not style typized-after 60 months. Two pts (0.8%) had gallbladder cancer (1 pt after 52 months; 1 pt after 67), 1 pt (0.4%) had a stomach cancer after 6 months interruption of therapy with TAM for 96 months, I pt (0.4%) had a pancreas cancer after 51 months. In conclusion, our results reflect the literature about the risk of a secondary endometrial cancers in long term treated pts (Lancet 1989, i, 117); the correlation between TAM and endometrial cancer is sure; there is no evidence of correlation with other tumors. We suggest periodic gynaecological control in patients treated with TAM for more than two years.

Published
1995

245. Pediculosi del capo.

Author

G., Scanni and E., Bonifazi

Abstract

La storia della pediculosi del capo si intreccia strettamente con la storia milionaria dell'uomo, portando elementi a favore della teoria evoluzionista. In una malattia dalla storia così antica emergono due novità degne di rilievo. L'immissione in commercio alla fine degli anni '90 di un prodotto a base di noce di cocco, anice e ylang-ylang ha rivoluzionato il mercato dei pediculocidi, tanto che da quell'epoca non compaiono più in commercio nuovi prodotti ad azione neurotossica, ma soltanto versioni diverse di pediculocidi ad attività fisica. L'altra novità è stata l'avvento dell'entodermoscopia, una nuova scienza che ha permesso al dermatologo di studiare "in vivo" l'anatomia, la fisiologia e la biologia del pidocchio, aiutandolo nel difficile compito di stabilire la vitalità di una colonia di pidocchi. [ABSTRACT FROM AUTHOR]

Published
2008

246. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: results of a multicentric Italian study. Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group.

Author

Boccardo, F, primary, Rubagotti, A, additional, Bruzzi, P, additional, Cappellini, M, additional, Isola, G, additional, Nenci, I, additional, Piffanelli, A, additional, Scanni, A, additional, Sismondi, P, additional, and Santi, L, additional

Published
1990
Full Text
View/download PDF

247. Tamoxifene (TAM) and primary breast cancer in old women

Author

Mustacchi, G., primary, Mansutti, M., additional, Milani, S., additional, Pluchinotta, A., additional, Farris, A., additional, Scanni, A., additional, Maiorino, L., additional, Santoro, A., additional, Traina, A., additional, Schieppati, G., additional, Malloci, A., additional, Zadro, A., additional, D'Aiuto, G., additional, Parisi, V., additional, Capasso, I., additional, Villa, E., additional, Fosser, V., additional, Garattini, P., additional, Schittulli, F., additional, Gambrosier, P., additional, De Fabiani, E., additional, Caciotto, C., additional, and Lombardi, M., additional

Published
1990
Full Text
View/download PDF

250. Primary treatment with tamoxifen in elderly patients with localised breast cancer

Author

M. Dimaiuta, F. Boioli, S. Cobelli, A. Scanni, R. Riundi, G. Schieppati, and E. Cardini

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, Cancer, medicine.disease, Breast cancer, Internal medicine, medicine, Primary treatment, business, Tamoxifen, medicine.drug
Published
1993

Catalog

Books, media, physical & digital resources
See catalog results